Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome with Baricitinib, a Janus Kinase Inhibitor
Jianqiu Yang,Chunyu Yuan,Shengru Zhou,Zhicheng Teng,Min Li
DOI: https://doi.org/10.2147/ccid.s446468
2024-03-05
Clinical Cosmetic and Investigational Dermatology
Abstract:Jianqiu Yang, 1, 2 Chunyu Yuan, 1 Shengru Zhou, 1 Zhicheng Teng, 2 Min Li 1 1 Department of Dermatology, Dushu Lake Hospital Affiliated to Soochow University (Medical Center of Soochow University), Suzhou, People's Republic of China; 2 Suzhou Medical College of Soochow University, Suzhou, People's Republic of China Correspondence: Min Li, Department of Dermatology, Dushu Lake Hospital Affiliated to Soochow University (Medical Center of Soochow University), No. 9, Chongwen Road, Suzhou, 215100, People's Republic of China, Tel +86-18936140383, Email Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome, a rare immune-mediated inflammatory disease, poses diagnostic and therapeutic challenges owing to its multi-system involvement, high heterogeneity, and lack of specific laboratory tests. Additionally, lacking evidence-based treatment recommendations, with the primary approach focusing on symptomatic relief. Herein, we report the case of a 32-year-old Chinese woman who presented with recurrent, generalized multiple osteoarticular pain lasting over one year and skin erythema pustulosis for 11 months. Traditional treatments, including non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and other traditional approaches, yielded no significant effects. Despite the prior use of adalimumab and acitretin capsules, the treatment remained unsatisfying, especially regarding the skin lesions. Considering the complex pathogenesis of SAPHO syndrome, the patient was orally administered baricitinib (2 mg), a Janus kinase (JAK) inhibitor, twice daily. A notable improvement in both skin lesions and osteoarticular pain was observed within two weeks of treatment initiation. Subsequently, the dosage of baricitinib was halved and continued for an additional three months, during which regular follow-ups revealed neither disease recurrence nor adverse effects. Collectively, the successful treatment of refractory SAPHO syndrome with baricitinib presents a promising implication for addressing the therapeutic challenges of this rare autoimmune condition, offering a potential breakthrough in managing its complex manifestations. Keywords: SAPHO syndrome, autoinflammatory conditions, therapeutic challenges, baricitinib Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare autoimmune disease and can be considered as an autoinflammatory condition. 1 This syndrome is primarily characterized by chronic aseptic inflammation affecting the skin, bones, and joints, presenting clinical rarity with no precise data on its prevalence, especially among different ethnic groups. 2 Although previous studies explored the genetic susceptibility, infection, and immune dysfunction associated with SAPHO, the exact etiology and pathogenesis of this disease remain incompletely elucidated. 1,3–5 Whole exome sequencing(WES) and Variant Enrichment Analysis(VEA) have been used to investigate the complex pathogenic landscape of SAPHO syndrome and other related autoinflammatory syndromes. WES was used to identify polygenic variants in patients with overlapping pyoderma gangrenosum, acne, and hidradenitis suppurativa (PASH)/SAPHO, and VEA was used to explore molecular mechanisms and etiopathogenic pathways involved in its onset. This approach revealed impaired macroautophagy pathways in patients with PASH/SAPHO. Autophagy deficiency in endothelial cells (EC) results in unregulated leukocyte transendothelial migration, increasing neutrophil infiltration and tissue damage. Moreover, enriched exclusive pathways (eEP) are associated with extracellular matrix organization in SAPHO patients. 6,7 Due to the involvement of multiple systems, high heterogeneity, and a lack of specificity in laboratory tests, diagnosing and treating this disease pose significant challenges. Currently, standardized treatment guidelines for SAPHO syndrome are lacking, and the primary therapeutic strategy involves symptomatic relief to alleviate pain, control inflammation, and enhance the overall quality of life of patients. 8,9 In recent years, the therapeutic strategies consisting of a combination of biologics and small molecules have brought new promising options for patients. In this study, we present a case of SAPHO syndrome unresponsive to conventional therapy that was effectively treated with an oral Janus kinase (JAK) inhibitor, baricitinib. A 32-year-old woman presented with sternal pain one year ago, followed by pain in the left articulatio humeri, spine, and right ankle with limited activity. A month later, erythema and pustules appeared on the surfaces of the soles, and the lesions gradually expanded. Diffuse psoriasis-like lesions appeared on -Abstract Truncated-
dermatology